Veru (VERU) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
28 Jan, 2026Executive summary
Annual meeting scheduled for March 12, 2026, at the company's Miami office.
Shareholders are invited to vote on key proposals, including director elections and executive compensation.
Voting can be done online, by mail, or in person at the meeting.
Voting matters and shareholder proposals
Election of six directors: Mitchell S. Steiner, Harry Fisch, Michael L. Rankowitz, Grace Hyun, Lucy Lu, and Loren Katzovitz.
Ratification of Cherry Bekaert LLP as independent auditor for fiscal year ending September 30, 2026.
Amendment to the 2018 Equity Incentive Plan.
Advisory vote on executive compensation (say-on-pay).
Approval to adjourn the meeting if necessary to solicit additional proxies.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and plan amendments.
Proxies are authorized to vote on additional matters that may arise at the meeting.
Latest events from Veru
- Enobosarm-GLP-1 combo targets muscle, fat, and bone health in obesity, with pivotal data due Q4 2027.VERU
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch amid going concern risk.VERU
Q1 202611 Feb 2026 - Q3 net loss narrowed, cash rose, and full enrollment reached in key obesity drug trial.VERU
Q3 20242 Feb 2026 - Leadership transition, integration focus, and strong China growth drive future profitability.VERU
Jefferies Global Healthcare Conference1 Feb 2026 - Proxy covers director elections, auditor ratification, equity plan changes, and executive pay.VERU
Proxy Filing28 Jan 2026 - Enobosarm aims to preserve muscle and function during GLP-1-induced weight loss, with key trial data due in 2025.VERU
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Enobosarm preserved muscle, increased fat loss, and improved function in older adults on GLP-1s.VERU
Study Result9 Jan 2026 - Strong clinical progress and improved financial position, but liquidity risks remain high.VERU
Q1 202524 Dec 2025 - Enobosarm combo therapy preserved muscle, boosted fat loss, and narrowed net loss.VERU
Q4 202517 Dec 2025